Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
ACRV
ACRV
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest ACRV ETF News Today | Earnings, Events & Price Alerts
ACRV News
FDA's Accelerated Approval Framework Drives Cancer Treatment Advances
Feb 17 2026
Newsfilter
Oncolytics Biotech Strengthens Leadership Amid Oncology Market Surge
Jan 28 2026
PRnewswire
Oncolytics Biotech Strengthens Leadership to Advance Clinical Programs
Jan 28 2026
Newsfilter
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
Jan 09 2026
NASDAQ.COM
Acrivon Therapeutics (ACRV) Shares Plunge 28.71% Following Mixed Phase 2b Clinical Results
Jan 08 2026
NASDAQ.COM
Acrivon Updates ACR-368 Phase 2 Data, Reports 39% ORR in Endometrial Cancer
Jan 08 2026
Benzinga
U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction
Jan 08 2026
Benzinga
Acuity Inc. Reports 20.2% Revenue Growth in Q1 2026
Jan 08 2026
Benzinga
Acrivon Reports 52% cORR for ACR-368 in Phase 2b Endometrial Cancer Trial
Jan 08 2026
NASDAQ.COM
NASDAQ 100 Pre-Market Indicator Falls, ACRV Trades Over 23 Million Shares
Jan 08 2026
NASDAQ.COM
AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%
Jan 08 2026
Benzinga
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
Jan 08 2026
NASDAQ.COM
Acrivon Therapeutics to Present Updated ACR-368 Data on January 8, 2026
Jan 07 2026
NASDAQ.COM
Acrivon to Provide ACR-368 Clinical Data Updates in January 2026 Conference Call
Dec 17 2025
Newsfilter
HC Wainwright & Co. Affirms Buy Rating for Acrivon Therapeutics, Keeps $19 Price Target Intact
Nov 25 2025
Benzinga
Top Analysts Recommend 3 Best Stocks to Purchase Now, 11/14/2025
Nov 14 2025
TipRanks
Show More News
